GLOBAL DNA VACCINE MARKET FORECAST 2018-2026

  • You are here:
  • Home
  • Reports
  • GLOBAL DNA VACCINE MARKET FORECAST 2018-2026

GLOBAL DNA VACCINE MARKET FORECAST 2018-2026

 The Global DNA vaccine market is anticipated to grow at a CAGR of 41.89% between 2018 and 2026. DNA vaccines can induce a wide range of immune responses and hence are extensively researched for potential benefits to cure diseases such as HIV-aids, cancer, and others.  The DNA vaccines market is primarily driven by following factors: DNA vaccines showing great promise in checking the rising prevalence of disease

GLOBAL DNA VACCINE MARKET FORECAST 2018-2026

DNA Vaccine Market by Type (Animal DNA Vaccine, Human DNA Vaccine) by Application (Human Disease, Veterinary Disease) by Technology (Plasmid DNA Vaccines, Plasmid DNA Delivery) by Geography

Request free sample

The Global DNA vaccines market is anticipated to grow at a CAGR of 41.89% between 2018 and 2026. DNA vaccines can induce a wide range of immune responses and hence are extensively researched for potential benefits to cure diseases such as HIV-aids, cancer, and others.  The DNA vaccines market is primarily driven by following factors:

  • DNA vaccines showing great promise in checking the rising prevalence of disease
  • Third generation vaccination is seeing a surge of investment
  • Increasing adoption of DNA vaccines for animal healthcare

The important driver increasing growth in the global DNA vaccines market is the increasing adoption of DNA vaccines for animal healthcare. Animals play an increasingly important role in society, for both, the developed and the developing world. As the global travel of animals, commercial goods, and people expand, chances of transmission of disease pose a greater threat than ever before. The demand for animal vaccines must be met in a timely, efficient and economically viable manner.

The applications of DNA vaccines market are used extensively for various purposes. DNA vaccines have the potential application in the anticipation and insurance for people suffering from any illnesses., including tuberculosis, flu, cancer and others. DNA vaccines are adroitly steadier and more secure when contrasted with the traditional vaccines approaches. It is because of plasmids that are non-recreating and non-living and bear no or little hazard for the auxiliary contamination and inversion of the infection causing state. DNA vaccines also have a potential application in the counteractive action and insurance of veterinary illnesses. It can be connected to the insurance of different ailments in animals, for example, canine melanoma, Leishmaniasis, West Nile infection and others. The DNA vaccines are considered as a novel technique for vaccination of many veterinary maladies. There are distinctive sorts of antibodies which exist for buddy animals. They include core vaccines, (for example, parvovirus, rabies, and distemper) that are required by companion animals, (for example, felines and canines), paying little mind to the danger of presentation or geographic area.

Lengthy regulatory process and poor patent protection in some countries are the major factors hindering the DNA vaccines market. Stringent government tenets and directions with regards to the utilization of DNA vaccines are hampering the growth of the global DNA vaccines market. However, plasmids DNA-based antibodies have been endorsed for veterinary use. Be that as it may, DNA vaccines for humans are still under clinical trials. Developing nations like India need strong regulatory and moral systems for taking care of clinical trials. In the U.S., the current law ensures privileges for the candidates through several prerequisites which incorporate a survey of research by Institutional Review Boards. This IRB limits chance for supporters and balances out damage advantage proportions.

The Global DNA vaccines market segments include types, applications, and technologies.

Types are segmented into:

  • Human DNA vaccine
  • Animal DNA vaccine

Applications are segmented into:

  • Human diseases
  • Veterinary diseases

Technologies are segmented into:

  • Plasmid DNA Delivery
  • Plasmid DNA vaccines

This report covers the present market conditions and the growth prospects of the global DNA vaccines market for 2018-2026 and considered the revenue generated through the sales of DNA vaccines for types, applications, and technologies to calculate the market size, by considering 2017 as the base year.

Geographically, the global DNA vaccines market has been segmented on the basis of four major regions, which include:

The DNA vaccines market in North America is expected to hold the largest share by 2026. Major contribution is expected from the United States and Canada because of an upgrade in the predominance of incessant and irresistible sicknesses in humans as well animals in this region. The DNA vaccines are useful for counteracting the action of sicknesses; which fundamentally incorporates HIV, HPV, cardiovascular ailments, measles and foot and mouth ailments. Then again, the Asia-Pacific market is expected to be the quickest developing locale for the Global DNA vaccines market. Asia Pacific DNA vaccines market is determined by various key drivers including, rising interests in DNA vaccines; innovative work, especially, in third generation vaccination,  innovation in clinical trials,  government support, etc.

The DNA vaccines Market is segmented on the basis of types which are sub-divided into Human DNA vaccine, Animal DNA vaccine and is also segmented on the basis of technologies which are sub-divided into Plasmid DNA Delivery and Plasmid DNA vaccines.  DNA vaccines are considered as an imperative and new strategy for vaccination for animals. Animal DNA vaccines depend on the strategy for exchanging hereditary material to substantial cells in the animal body with the reason for affecting invulnerable framework. Animal DNA vaccination includes the procedure of vaccination through a plasmid encoding an antigen of a pathogen. Vaccination is a standout amongst the best uses of immunological standards to human well-being. Human DNA vaccines give a powerful and basic method for creating wide based resistance. DNA (deoxyribonucleic corrosive) vaccination is a novel innovation which delivers an immunological reaction by utilizing hereditarily built DNA. Plasmid DNA Vaccine innovation can be used economically for the large-scale generation of veterinary DNA Vaccines as they offer focal points. For example, they initiate both cell and humoral cell reactions. Plasmid DNA conveyance innovation is utilized to convey the vaccines inside the DNA Vaccineular incorporation of a ring. This ring can reproduce in a self-sufficient way. Distinctive conveyance modes that are utilized to convey plasmid into cell incorporate gold molecule, Liposome-intervened conveyance, nanoparticles, and infection.

The major market players in the global DNA vaccines market are:

  • MADISON VACCINES INCORPORATED (MVI)
  • EUROGENTEC S.A
  • SANOFI
  • NOVARTIS AG
  • INOVIO PHARMACEUTICALS, INC.

Company Profiles covers analysis of important players.

Madison Vaccines Incorporated is as clinical stage biopharmaceutical organization which focuses on advancing innovative cancer therapies. Another company, Inovio Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company, based in the United States which was incorporated in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. The company is mainly engaged in active DNA immunotherapies and vaccines in a grouping with proprietary electroporation delivery devices to prevent and treat infectious diseases and cancers.

Key Findings of the Global DNA vaccines market:

  • Active clinical trials for human DNA vaccine is fueling the market growth
  • North America is a global leader in the DNA vaccine market
  • Veterinary diseases lead the application segment of the DNA vaccine market
  • Cancer treatments are an important focus of the DNA vaccine clinical trials
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • ACTIVE CLINICAL TRIALS FOR HUMAN DNA VACCINE IS FUELING THE MARKET GROWING POTENTIAL
      • NORTH AMERICA IS THE GLOBAL LEADER IN DNA VACCINE MARKET
      • VETERINARY DISEASES LEADS THE APPLICATION SEGMENT OF THE DNA VACCINE MARKET
      • CANCER TREATMENT ARE AN IMPORTANT FOCUS FOR DNA VACCINE CLINICAL TRIALS
  1. MARKET DETERMINANTS
    • DRIVERS
      • DNA VACCINES SHOWS GREAT PROMISE IN CHECKING RISING PREVALENCE OF DISEASE
      • THIRD GENERATION VACCINATION IS SEEING A SURGE OF INVESTMENT
      • INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE
    • RESTRAINTS
      • LENGTHY REGULATORY PROCESS
      • POOR PATENT PROTECTION IN SOME COUNTRIES
    • OPPORTUNITIES
      • TRANSFORMING HEALTHCARE LANDSCAPE
      • NEW DEVELOPMENTS IN BIOTECHNOLOGIES AND NANOTECHNOLOGIES
      • STABLE VACCINES MAKE IT ATTRACTIVE TO STORE AND TRANSPORT
    • CHALLENGES
      • VACCINES FOR HUMAN USAGE STILL UNDER CLINIC TRAIL PHASE
  1. MARKET SEGMENTATION
    • MARKET BY TYPE 2018-2026
      • ANIMAL DNA VACCINE
      • HUMAN DNA VACCINE
    • MARKET BY APPLICATION 2018-2026
      • HUMAN DISEASE
      • VETERINARY DISEASE
    • MARKET BY TECHNOLOGY 2018-2026
      • PLASMID DNA VACCINES
      • PLASMID DNA DELIVERY
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • THREATS OF SUBSTITUTE PRODUCT
      • BARGAINING POWER OF BUYER
      • BARGAINING POWER OF SUPPLIER
      • INTENSITY OF COMPETITIVE RIVALRY
    • KEY BUYING CRITERIA
      • EFFICACY
      • COST-EFFECTIVENESS
      • STABILITY
    • KEY MARKET PLAYERS
      • VICAL INCORPORATED
      • SANOFI
      • MERCK AND CORP
      • GSK
    • OPPORTUNITY MATRIX
    • VALUE CHAIN ANALYSIS
      • R&D
      • MANUFACTURING
      • RAW MATERIALS
      • MARKETING, DISTRIBUTION & END USER
    • LEGAL, POLICY AND REGULATORY FRAMEWORK
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • UNITED STATES
      • CANADA
    • EUROPE
      • UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • REST OF ASIA PACIFIC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPETITIVE LANDSCAPE
    • STRATEGIC INITIATIVES
      • ACQUISITION
      • PARTNERSHIP
      • COLLABORATION
      • INNOVATION
      • DISINVESTMENT
      • EXPANSION
  1. COMPANY PROFILE
    • MARKET SHARE
    • ASTELLAS PHARMA INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • ELI LILLY AND COMPANY
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • EUROGENTEC S.A
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • GLAXOSMITHKLINE
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • INOVIO PHARMACEUTICALS, INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • MADISON VACCINES INCORPORATED (MVI)
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • MERCK & CO.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • NOVARTIS AG
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • SANOFI
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • VGXI
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • VICAL INCORPORATED
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • XENETIC BIOSCIENCES INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATES
    • ZOETIS INC
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATES

LIST OF TABLES

TABLE 1                 GLOBAL DNA VACCINE MARKET BY GEOGRAPHIES 2018-2026 ($ MILLION)

TABLE 2                 INTERVENTIONS AND PHASE OF CERTAIN DISEASE/CONDITIONS

TABLE 3                 APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY

TABLE 4                 CLINICAL TRIALS OF THE HUMANS INVOLVING DNA VACCINES

TABLE 5                 TEMPERATURE REQUIREMENTS IN PRESERVATION FOR VARIOUS VACCINES

TABLE 6                 GLOBAL DNA VACCINE MARKET BY TYPE 2018-2026 ($ MILLION)

TABLE 7                 GLOBAL DNA VACCINE MARKET IN ANIMAL DNA VACCINE BY GEOGRAPHY 2018-2026($MILLION)

TABLE 8                 GLOBAL DNA VACCINE MARKET IN HUMAN DNA VACCINE BY GEOGRAPHY 2018-2026

TABLE 9                 GLOBAL DNA VACCINE MARKET BY APPLICATION 2018-2026 ($ MILLION)

TABLE 10     GLOBAL DNA VACCINE MARKET IN HUMAN DISEASES APPLICATION BY GEOGRAPHY 2018-2026 ($MILLION)

TABLE 11     GLOBAL DNA VACCINE MARKET IN VETERINARY APPLICATION BY GEOGRAPHY 2018-2026

TABLE 12     GLOBAL DNA VACCINE MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)

TABLE 13     GLOBAL DNA VACCINE MARKET IN PLASMID DNA VACCINES TECHNOLOGY BY GEOGRAPHY 2018-2026

TABLE 14     GLOBAL DNA VACCINE MARKET IN PLASMID DNA DELIVERY TECHNOLOGY BY GEOGRAPHY 2018-2026

TABLE 15     REGULATIONS TO BE FOLLOWED BEFORE COMMERCIALIZATION

TABLE 16     GLOBAL DNA VACCINES MARKET, BY GEOGRAPHIES 2018-2026 ($ MILLION)

TABLE 17     NORTH AMERICA DNA VACCINE MARKET 2018-2026 ($ MILLION)

TABLE 18     EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)

TABLE 19     ASIA PACIFIC DNA VACCINES MARKET 2018-2026 ($ MILLION)

TABLE 20     REST OF THE WORLD DNA VACCINES MARKET 2018-2026 ($ MILLION)

FIGURE LIST

FIGURE 1     GLOBAL DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 2     NORTH AMERICA DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 3     GLOBAL DNA VACCINE MARKET IN VETERINARY DISEASES 2018-2026 ($ MILLION)

FIGURE 4     SHARE OF TRIALS BY VACCINE TARGET IN 2016

FIGURE 5     SEGMENT OF CLINICAL TRIALS OF DNA VACCINE BY CANCER MARKS IN 2016

FIGURE 6     CLINICAL TRIALS OF GENE THERAPHY

FIGURE 7     GLOBAL DNA VACCINE MARKET SHARE BY TYPE 2017 & 2026 (%)

FIGURE 8     GLOBAL DNA VACCINES MARKET IN ANIMAL DNA VACCINES 2018-2026 ($ MILLION)

FIGURE 9     GLOBAL DNA VACCINE MARKET IN HUMAN DNA VACCINES 2018-2026($ MILLION)

FIGURE 10   GLOBAL DNA VACCINE MARKET SHARE BY APPLICATION 2017 & 2026 (%)

FIGURE 11   GLOBAL DNA VACCINES MARKET IN HUMAN DISEASES 2018-2026 ($ MILLION)

FIGURE 12   GLOBAL DNA VACCINES MARKET IN VTERINARY APPLICATION 2018-2026 ($ MILLION)

FIGURE 13   GLOBAL DNA VACCINES MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026 ($ MILLION)

FIGURE 14   GLOBAL DNA VACCINES MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026 ($ MILLION)

FIGURE 15   VALUE CHAIN ANALYSES FOR DNA VACCINE INDUSTRY

FIGURE 16   UNITED STATES DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 17   CANADA DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 18   UNITED KINGDOM DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 19   FRANCE DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 20   GERMANY DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 21   SPAIN DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 22   REST OF EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 23   INDIA DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 24   CHINA DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 25   JAPAN DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 26   AUSTRALIA DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 27   REST OF ASIA PACIFIC DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 28   LATIN AMERICA DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 29   MENA DNA VACCINE MARKET 2018-2026 ($ MILLION)

FIGURE 30   MARKET SHARES OF TOP FIVE COMPANIES FOR DNA VACCINES MARKET IN 2017

  1. MARKET SEGMENTATION
    • MARKET BY TYPE 2018-2026
      • ANIMAL DNA VACCINE
      • HUMAN DNA VACCINE
    • MARKET BY APPLICATION 2018-2026
      • HUMAN DISEASE
      • VETERINARY DISEASE
    • MARKET BY TECHNOLOGY 2018-2026
      • PLASMID DNA VACCINES
      • PLASMID DNA DELIVERY
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • UNITED STATES
      • CANADA
    • EUROPE
      • UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • REST OF ASIA PACIFIC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now